A study published in 2020 evaluated AuraSTOP® in children and adolescents suffering from primary headaches, in the absence of other comorbidities.
The hiring of AuraSTOP®, conducted for three months with the use of two sachets a day, was monitored weekly through telephone contacts or e-mails with parents to verify the compliance of the subjects.
The study used several measurement tools to evaluate the effectiveness of the treatment
42 children and adolescents (25 girls and 17 males) with an average age of 10.59 ± 3.18 years were included in the study. After three months of taking, the results showed significant improvements:
The intake of AuraSTOP© in children and adolescents, limited to the case studies studied, showed a significant reduction in the number of days of headache, perceived pain and associated disability, significantly improving the impact of headache on the quality of life.
Limitations: The study offers interesting preliminary data, but does not provide definitive evidence of efficacy due to the absence of controlled design and small samples.
(Dal Volta G., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy triptohan and magnesium (AuraSTOP) in the prevention of high frequency migraine with aura. Open Access Library. 2018;5,E4939)
(Dal Volta G., et al. Comparison of the effect of Tanacethum parthenium, 5-hydroxy tryptophan, and magnesium (AuraSTOP) versus magnesium alone on aura phenomenon and ITS Evolution. Pain Research and Management. 2019;6320163)
(Mainardi F., et al. Efficacy of a combination of tanacetum parthenium, 5-hydroxy tryptohan and magnesium (AuraSTOP) in Episodic migraine prevention: a multicentric Observational Study Open Access Library Journal 2018;5,E4765).
(Zavarise P., et al. Combination of Tanacethum Partenium, 5-Hydroxitriptophan (5-HTTP) and Magnesium in the Prophylaxis of Episodic migraine without aura (Aurastop®) An observational study.
